Editorial: The Guardian

• Drug supply is a global issue, worsened by Brexit in the UK.
• Drug manufacturers face competing demands for limited ingredients.
• Around 100 medicines are on a shortage list and the government appears under‑prepared and slow to act.
• Dependence on India and China for drug manufacturing capacities highlighted risks during the pandemic.
• The EU and US are making moves towards reshoring production.
• Brexit and the fall in the pound's value has made the UK a less attractive market.
• A balance is needed between keeping drug prices low and incentivising suppliers.
• Access to medicines is vital, and the UK government needs a strategy.

Conclusion: Brexit has exacerbated the UK's drug supply chain challenges. A strategy that includes working with the EU to reshore production is crucial to deal with the current challenges.

---